1. 168P Liver metastases (mets) and treatment effect of cemiplimab-based therapy: An analysis from three phase III trials (EMPOWER-Lung 1, EMPOWER-Lung 3 part 2, and EMPOWER-Cervical 1). (December 2022) Authors: Baramidze, A.; Gessner, C.; Gogishvili, M.; Sezer, A.; Makharadze, T.; Kilickap, S.; Gumus, M.; Tewari, K.S.; Monk, B.J.; de Melo, A.C.; Oaknin, A.; Li, S.; Gao, B.; Mathias, M.D.; Gullo, G.; Salvati, M.E.; Seebach, F.; Lowy, I.; Fury, M.; Rietschel, P. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 196TiP A phase I study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies. (December 2022) Authors: Lakhani, N.; Hamid, O.; Braña, I.; Reguera Puertas, P.; Lopez Criado, M.P.; Swiecicki, P.L.; De Miguel Luken, M.J.; Gil Martín, M.; Khong, H.; Moreno Garcia, V.; Lostes Bardaji, M.J.; Sun, F.; Sandigursky, S.; Zambrano, M.; Cristea, M.; Fury, M. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2874 Impact of white adipose tissue inflammation on survival in patients with squamous cell carcinoma of the oral tongue. (September 2015) Authors: Iyengar, N.; Ghossein, R.; Kochhar, A.; Morris, L.; Zhou, X.; Morris, P.; Awad, M.; Fury, M.; Pfister, D.; Patel, S.; Boyle, J.; Hudis, C.; Dannenberg, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗